Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
THE CLINICAL VALUE OF BIOELECTRICAL PHASE ANGLE IN HEART FAILURE
Session:
Sessão de Posters 39 - Insuficiência cardíaca: abordagem a longo prazo
Speaker:
Bruno Bragança
Congress:
CPC 2024
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.6 Chronic Heart Failure - Clinical
Session Type:
Cartazes
FP Number:
---
Authors:
Bruno Bragança; Rafaela G. Lopes; Inês G. Campos; Mauro Moreira; Ricardo Barbosa; Magda Silva; Sónia Apolinário; Patrícia Silva; Licínia Aguiar; Aurora Andrade
Abstract
<p style="text-align:justify"><strong>Background: </strong>Phase angle (PhA) is an emerging biomarker derived from bioimpedance vector analysis (BIVA) between cells’ resistance (R) and reactance (Xc) to the passage of electric current through the body. PhA levels correlate with cellular integrity, with low levels being found in several diseases as well as in subjects with low cardiorespiratory fitness<sup>1</sup>. Notwithstanding, few data regarding PhA on heart failure (HF)<sup>2</sup> are available.</p> <p style="text-align:justify"><strong>Methods: </strong>Patients with chronic HF (mean left ventricular ejection fraction (LVEF) of 34±13) and 13 healthy subjects were recruited for BIVA. Whole-body PhA at 50Hz was measured through an octa-polar electrode (InBody BWA 2.0). BIVA was correlated with other clinical and biochemical parameters in HF patients. HF patients were prospectively followed up to 6±1 months for the occurrence of the composite adverse event: all-cause death, hospitalization/unplanned visit, or up-titration of diuretics due to HF.</p> <p style="text-align:justify"><strong>Results: </strong>PhA was lower in HF patients than in controls (5.87±1.48 vs 7.04±0.98º, p=0.009); resistance (R, 229±56.9 vs 233±44.3Ω, p=0.836) and reactance (Xc, 23.1±5.5 vs 28.4±4.9Ω; p=0.002). In comparison with age-matched subjects from vendor database, HF patients had less -1.1±1.8º PhA. PhA was inversely associated with NT-proBNP levels (r=-0.423; p=0.003), but not with LVEF (r=0.1, p=0.943). Stratifying according to PhA quartiles, patients in the lowest quartile (PhA < 4.95º; 4.13±0.7º, n=14) were older (74±9 vs 62±10 years; p<0.001), had lower levels of hemoglobin (12.9±2 vs 14.3±2 years; p<0.02) and higher levels of urea-to-creatinine ratio (54.9±10 vs 43.5±9; p<0.001). In the event-free survival analysis, the group with the lowest PhA was significantly associated with the composite outcome (HR 4.36±2.7; p<0.03). </p> <p style="text-align:justify"><strong>Conclusions:</strong> PhA is associated with surrogate markers of HF severity. Patients with low PhA will possibly benefit from the intensification of specific HF therapies, but this needs to be confirmed in further studies.</p> <p><span style="font-size:8px">1 – H. Salmons, et al., Journal of Cardiac Failure, 2023 | 2 – P. Scicchitano, et al. Rev Endocr Metab Disord. 2023</span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site